Association of autoimmune type atrophic corpus gastritis with Helicobacter pylori infection by Veijola, Lea Irene et al.
BRIEF ARTICLE 
Association of autoimmune type atrophic corpus gastritis 
with Helicobacter pylori  infection
Lea Irene Veijola, Aino Mirjam Oksanen, Pentti Ilmari Sipponen, Hilpi Iris Kaarina Rautelin
World J Gastroenterol  2010 January 7; 16(1): 83-88
 ISSN 1007-9327 (print)




83 January 7, 2010|Volume 16|Issue 1|WJG|www.wjgnet.com
Lea Irene Veijola, Aino Mirjam Oksanen, Herttoniemi 
Hospital, City of Helsinki, Kettutie 8, 00800 Helsinki, Finland
Lea Irene Veijola, Hilpi Iris Kaarina Rautelin, Department of 
Bacteriology and Immunology, Haartman Institute, University 
of Helsinki, Haartmanink. 3, 00014 Helsinki, Finland
Pentti Ilmari Sipponen, Repolar Oy, Box 26, 02101 Espoo, 
Finland
Hilpi Iris Kaarina Rautelin, HUSLAB, Helsinki University 
Central Hospital Laboratory, Haartmanink 3, 00014 Helsinki, 
Finland; Department of Medical Sciences, University of Uppsala, 
Dag Hammarskjölds väg 17, SE-75185 Uppsala, Sweden
Author contributions: Veijola LI, Rautelin HIK and Oksanen 
AM planned the study; Veijola LI and Oksanen AM interviewed 
and examined the patients, and performed the gastroscopies; 
Sipponen PI examined the histology of the biopsy materials; 
Veijola LI analyzed the data; Veijola LI and Rautelin HIK 
wrote the article; all authors participated in the revision of the 
manuscript.
Correspondence to: Lea Irene Veijola, MD, PhD, Herttoniemi 
Hospital, City of Helsinki, Kettutie 8, 00800 Helsinki, 
Finland. lea.veijola@helsinki.fi
Telephone: +358-9-3105511     Fax: +358-9-19126382
Received: September 27, 2009  Revised: November 16, 2009
Accepted: November 23, 2009
Published online: January 7, 2010
Abstract
AIM: To study the association between Helicobacter 
pylori  (H. pylori ) infection and autoimmune type 
atrophic gastritis.
METHODS: Twenty-three patients with different 
grades of atrophic gastritis were analysed using enzyme 
immunoassay-based serology, immunoblot-based 
serology, and histology to reveal a past or a present 
H. pylori  infection. In addition, serum markers for 
gastric atrophy (pepsinogen Ⅰ, pepsinogen Ⅰ/Ⅱ and 
gastrin) and autoimmunity [parietal cell antibodies (PCA), 
and intrinsic factor (IF), antibodies] were determined.
RESULTS: Of the 14 patients with severe gastric 
atrophy, as demonstrated by histology and serum 
markers, and no evidence for an ongoing H. pylori  
infection, eight showed H. pylori  antibodies by 
immunoblotting. All eight had elevated PCA and 4/8 
also had IF antibodies. Of the six immunoblot-negative 
patients with severe corpus atrophy, PCA and IF 
antibodies were detected in four. Among the patients 
with low to moderate grade atrophic gastritis (all except 
one with an ongoing H. pylori  infection), serum markers 
for gastric atrophy and autoimmunity were seldom 
detected. However, one H. pylori  negative patient 
with mild atrophic gastritis had PCA and IF antibodies 
suggestive of a pre-atrophic autoimmune gastritis.
CONCLUSION: Signs of H. pylori  infection in autoim-
mune gastritis, and positive autoimmune serum mark-
ers in H. pylori  gastritis suggest an etiological role for 
H. pylori  in autoimmune gastritis.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Autoimmune type corpus gastritis, formerly named type 
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A gastritis, is severe atrophy of  gastric corpus associated 
with hypochlorhydria[1]. Even without total gastric 
atrophy, many of  these patients have an inability to 
absorb vitamin B12 from food[2]. Generally, 15%-20% of  
vitamin B12 malabsorption in elderly patients is due to 
pernicious anaemia, as defined as deficiency of  intrinsic 
factor (IF)[3]. Over 90% of  patients with pernicious 
anaemia have parietal cell antibodies (PCA) and 50%-70% 
have elevated IF antibodies[1]. The autoantigen for PCA is 
H+/K+-adenosine triphosphatase, the proton pump[4]. 
In patients with Helicobacter pylori (H. pylori) infection, 
superficial gastritis proceeds to atrophic gastritis in about 
half  of  the patients[5]. Although this type of  atrophic 
gastritis, which is associated with intestinal metaplasia, 
mainly involves the antrum, it can proceed to the corpus 
or affect the mucosa focally, viz. multifocal atrophic 
gastritis. Advanced atrophy develops over many years 
and H. pylori disappears from the gastric mucosa. In 
some patients, the antral intestinal metaplasia disappears 
and PCA appears; thus, the disease resembles classic 
autoimmune gastritis[6]. Gastric H+/K+-ATPase is 
also the major autoantigen in chronic H. pylori induced 
atrophic gastritis in corpus mucosa[7]. 
In H. pylori induced atrophic gastritis, the activated 
CD4+ Th1 cells infiltrating the gastric mucosa cross-
recognize the epitopes of  the gastric parietal cell proton 
pump and various H. pylori proteins[8,9]. It is not known 
if  H. pylori is the initiating factor in activating Th1 cells, 
which leads to inflammation and apoptosis, or is only 
a coincidental bystander[10]. If  the classic autoimmune 
type gastric atrophy is an end-stage of  H. pylori induced 
gastric autoimmunity with atrophic gastritis, the 
prevalence of  pernicious anaemia should decrease with 
declining prevalence of  H. pylori. It is not known if  
vitamin B12 malabsorption in the late stages of  gastric 
atrophy could be restored or prevented if  H. pylori were 
eradicated earlier[11-14]. 
In the present study we investigated the signs of  a 
previous H. pylori infection in patients with different 
grades of  atrophic gastritis to assess the proportion of  
gastric atrophy not associated with H. pylori infection.
MATERIALS AND METHODS
All patients with an earlier gastroscopy reprint available 
and who had undergone a gastroscopy for clinical 
indications at Herttoniemi Hospital during 2004 and 
2005[15] were included in the present study if  their 
follow-up histology indicated they had atrophic gastritis. 
Twenty-three of  the 38 patients with different grades of  
atrophic gastritis had a blood sample available and were 
included in the study. The median age was 65 years and 
18 were females.
The Ethics Committee of  the Hospital District of  
Helsinki and Uusimaa approved the study and all the 
participants gave their written informed consent.
Histology
Two biopsies from each of  the antrum and the corpus 
were taken during gastroscopy and stained with 
haematoxylin-eosin, Alcian blue (pH 2.5)-periodic acid 
Schiff, and modified Giemsa stains. All the samples 
were examined by one pathologist who was unaware of  
the identity of  the samples. The samples were assessed 
according to the updated Sydney system[16].
Serum tests
H. pylori antibodies were detected by an enzyme immu-
noassay (EIA) and by immunoblotting. Serum samples 
were taken after gastroscopy and stored (-20℃) until 
analyzed for IgG antibodies to H. pylori using a locally 
validated in-house EIA with high sensitivity and 
specificity[17]. Immunoblotting was performed by MP 
Diagnostics Helico blot 2.1 (MP Biomedicals, Singapore). 
The interpretation criteria for an H. pylori seropositive 
sample, according to the manufacturer, were: (1) fulfill-
ing the criteria for CagA positivity; (2) the presence 
of  any bands at 89 kDa, 37 kDa, or 35 kDa; or (3) the 
presence of  both the bands at 30 kDa and 19.5 kDa. 
The criteria for CagA positivity were the presence of  
116 kDa CagA band (a) in combination with current 
infection marker CIM; (b) in combination of  the 30 kDa 
(UreA) and 19.5 kDa bands; or (c) in combination of  at 
least one of  the following bands 89 kDa (VacA), 37 kDa, 
or 35 kDa.
PCA were measured by Varelisa (Pharmacia Diag-
nostics, Freiburg, Germany) using H+/K+-ATPase as 
an antigen. According to the manufacturer’s instructions, 
values > 15 U/mL were interpreted as positive but 
equivocal values (10-15 U/mL) were interpreted negative 
as well as values < 10 U/mL. 
Serum IF antibodies of  the blocking type were 
measured routinely with the haemoglobin charcoal 
adsorption assay. The cut off  value used was 2 U/L.
Serum pepsinogen Ⅰ and Ⅱ and gastrin-17 levels 
were investigated with Gastropanel (Biohit PLC Diag-
nostics, Helsinki, Finland). The reference ranges were 
30-120 μg/L for pepsinogen Ⅰ, 3-10 μg/L for pepsino-
gen Ⅱ, 3-20 for pepsinogen Ⅰ/Ⅱ, and 2-10 pmol/L for 
gastrin-17.
Statistical analysis
The differences between the groups were tested using 
two-tailed Fisher’s exact test and the data were analysed 
using GraphPad software (QuickCalcs online calculators 
for scientists www.graphpad.com). P values < 0.5 were 
considered significant.
RESULTS
Of  the 23 patients included in the study, 14 had severe 
gastric atrophy according both to histology and the 
serum markers, and the remaining nine patients had mild 
to moderate atrophic gastritis. The patients with severe 
atrophy were slightly younger (median age 64 years) 
than the other patients (median age 70 years). None 
of  the patients with severe atrophy had either H. pylori 
in histology or elevated H. pylori antibodies in the EIA 
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(Table 1); one patient had had a successful H. pylori 
eradication therapy 7 years earlier. Of  the nine patients 
with mild to moderate atrophic gastritis, two had had a 
successful eradication therapy (4 mo and 6 mo earlier, 
respectively) and four had an ongoing infection shown in 
histology; seven had elevated H. pylori antibodies in the 
EIA (Table 1). All patients, except one with moderate 
atrophic gastritis, had chronic gastritis in the corpus, 
whereas the antrum was significantly less often affected 
in patients with severe atrophy compared to those with 
mild and moderate atrophic changes (P = 0.04, Fisher’s 
exact test, Table 1). Antral intestinal metaplasia was not 
found in any of  the patients with severe atrophy. 
Serum markers for gastric autoimmunity were only 
rarely detected in patients with mild to moderate atrophic 
gastritis (PCA in three patients and IF antibodies in one 
patient, Table 1). In contrast, all 14 patients with severe 
atrophy had either elevated PCA or IF antibodies, six 
patients having both antibodies elevated. Furthermore, 
the levels of  elevated PCA and IF antibodies were higher 
in patients with severe atrophy (eight of  12 patients with 
elevated PCA had a PCA titre over 100, and the mean IF 
antibody titre in eight patients with an elevated value was 
8.7) compared to patients with only mild to moderate 
atrophic changes (only one of  the three patients with 
elevated PCA had a PCA titre over 100 and the IF 
antibody titre in the only patient with an elevated value 
was 2.1). 
H. pylori antibodies could be demonstrated by 
immunoblotting in 8/9 patients with mild to moderate 
atrophic gastritis and in 8/14 patients with severe gastric 
atrophy (Table 1). Patients with severe atrophy and a 
positive immunoblot result did not significantly differ 
from those with severe atrophy and negative immunoblot 
results as far as age, sex, histological findings, and serum 
results were concerned (Table 1). Although six patients 
with severe atrophy showed negative immunoblot results 
(according to the criteria of  the manufacturer) four of  
them had a positive CagA band in the immunoblot; 
thus, only two patients showed no evidence of  previous 
H. pylori infection. In addition, one patient with mild 
atrophic gastritis had no evidence (not even a CagA 
band) for ongoing or previous H. pylori infection 
(Table 1). This particular patient showed clearly elevated 
PCA (> 100 U/mL) and slightly elevated IF antibodies 
(2.1 U/L).
DISCUSSION
In our study, of  the 14 patients having autoimmune type 
atrophic gastritis (severe gastric atrophy with elevated 
PCA and/or IF antibodies) only two had no signs of  
previous H. pylori infection. In addition, all except one 
of  the patients with mild to moderate atrophic corpus 
gastritis had an ongoing H. pylori infection or signs 
of  previous infection. The H. pylori negative patient 
with minor atrophic changes in the gastric corpus had 
elevated PCA and IF antibodies; whether this particular 
patient goes on to develop severe gastric atrophy of  
autoimmune type remains to be shown. To the best of  
our knowledge, she is the first patient described in the 
literature as having preatrophic autoimmune gastritis 
with elevated serum markers of  pernicious anaemia and 
no signs of  H. pylori infection, despite being investigated 
with both invasive and non-invasive methods: antrum 
and corpus histology in two gastroscopies with a 5.4 years 
interval and negative EIA serology and immunoblotting, 
including CagA.
In severe gastric atrophy, the exclusion of  previous 
H. pylori infection is controversial, as the sensitivity 
of  histology is low[18], and many of  the EIA based 
serological tests are poorly validated[19]. In H. pylori 
gastritis, the antibodies in EIA serology decline below 
the cut-off  values along with advanced atrophy[20], as 
Findings                 Number of patients with atrophic corpus gastritis P -value
Grade 1 or 2 Grade 3 
IB+ (n = 8) IB- (n  = 1) Total IB+ (n  = 8) IB- (n  = 6) Total
Chronic corpus gastritis 7 1 8 8 6 14 NS
Chronic antral gastritis 7 1 8 3 3   6 0.04
Antral intestinal metaplasia 3 0 3 0 0   0 0.05
H. pylori in histology 4 0 4 0 0   0 0.01
Elevated EIA H. pylori IgG1 7 0 7 0 0   0     0.0001
Vitamin B12 therapy 1 0 1 4 6 10   0.009
Elevated PCA2 2 1 3 8 4 12 0.02
Elevated IF antibodies3 0 1 1 4 4   8 0.04
Low pepsinogen Ⅰ4 0 0 0 8 6 14     0.0001
Elevated pepsinogen Ⅱ5 5 0 5 4 1   5 NS
Low pepsinogen Ⅰ/Ⅱ6 1 0 1 8 6 14     0.0001
Elevated gastrin-177 2 1 3 8 5 13   0.005
1In-house EIA positive ≥ 700; 2Parietal cell antibodies PCA elevated > 15; 3Intrinsic factor IF elevated > 2; 4Pepsinogen Ⅰ low < 30; 
5Pepsinogen Ⅱ elevated > 10; 6Pepsinogen Ⅰ/Ⅱ low < 3; 7Gastrin 17 elevated > 10. EIA: Enzyme immunoassay; H. pylori: Helicobacter 
pylori; PCA: Parietal cell antibodies; IF: Intrinsic factor; NS: Not significant; IB+: Immunoblot positive; IB-: Immunoblot negative. 
P-value: Total (grade 1 or 2) vs total (grade 3).
Table 1  Histological and serum findings in patients with mild to moderate (n  = 9) and severe (n  = 14) 
atrophic changes in the corpus
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well as after eradication therapy[21]; thus, the previous 
H. pylori infection cannot be deduced by negative EIA 
serology. Immunoblotting with CagA antibodies can 
give positive results for years after the disappearance 
of  H. pylori[22,23], but all H. pylori strains are not CagA 
positive. Discrepancies in CagA seropositivity yielded 
by immunoblotting in patients with severe gastric 
atrophy[24,25] may derive from the different sensitivities of  
the immunoblotting methods used[26].
Studies of  patients with preatrophic autoimmune type 
of  corpus gastritis are rare. In a population-based study, all 
12 patients with autoimmune type atrophic gastritis (diffuse 
lymphocytic infiltration of  the entire lamina propria in the 
corpus mucosa) without severe gastric atrophy showed 
H. pylori in histology or serology[27]. In the same study, of  
the 28 individuals with severe autoimmune type gastric 
atrophy six were H. pylori positive in histology and another 
13 were positive in serology (altogether 68% positive 
for H. pylori). Considering the moderately high prevalence 
(2.8% in the Kalixanda study[27]) of  the autoimmune 
type of  gastric atrophy in general, the description in the 
literature of  patients with H. pylori negative autoimmune 
type gastritis in preatrophic stage is rare.
Uibo described a 17-year-old female with no signs 
of  gastritis and H. pylori in histology developing atrophic 
gastritis during a 12-year follow-up[28]. However, the ex-
clusion of  H. pylori infection in this case was based only 
on histology, and the childhood infection rate in this 
population cohort was nearly 100%. Kuipers described 
two patients who were negative for H. pylori and with-
out gastritis at first visit, who then developed atrophic 
gastritis (one developed also intestinal metaplasia and 
pernicious anaemia) during more than 10 years of  fol-
low-up[29]. However, although in this study the H. pylori 
infection was assessed with serology and histology at the 
first visit, in cases of  discrepant results, histology was 
considered predominant over serology unless atrophic 
mucosa was observed. Whether these two patients had 
positive serology at the first visit was not mentioned. In 
the study of  Segni et al[30] of  children with juvenile auto-
immune thyroid disease, of  the 18 children with elevated 
PCA who underwent gastroscopy, two children with 
hypergastrinaemia had H. pylori negative preatrophic gas-
tritis, as shown by histology and EIA serology. Immu-
noblotting was not studied and follow-up has not been 
published. In the study of  adult patients with Sjögren’s 
syndrome, there was no difference in the prevalence 
of  H. pylori infection, antigastric antibodies, or gastric 
histology between patients and controls, but after suc-
cessful eradication therapy for H. pylori, the lympho-
cytic infiltration and atrophy in patients with Sjögren’s 
syndrome, contrary to the controls, did not improve[31]. 
In addition, patients with Sjögren’s syndrome who were 
positive for antigastric antibodies all had H. pylori infec-
tion and they more often had atrophic gastritis than 
the controls. In conclusion, from the previous studies, 
patients with autoimmune type atrophic gastritis without 
H. pylori infection might rarely exist, but at the moment 
a study showing preatrophic gastritis proceeding to total 
gastric atrophy without H. pylori infection is lacking. This 
is in accordance with our results; as the patient having 
preatrophic gastritis without signs of  H. pylori infection 
did not proceed to total gastric atrophy during 5 years of  
follow-up. 
Several studies suggest that autoimmune atrophic 
corpus gastritis is associated with H. pylori infection 
in the majority of  cases. In one study, two-thirds of  
patients with atrophic corpus gastritis had evidence of  
H. pylori infection, when assessed with histology and 
serology[32]. In another study, 62% of  the patients with 
pernicious anaemia and severe atrophic corpus gastritis 
had positive H. pylori serology[33]. In one further study, 
patients with atrophic corpus gastritis were negative for 
H. pylori in histology and in EIA-serology, but positive 
when studied by immunoblotting[25]. In another study 
of  atrophic corpus gastritis, among 111 patients with 
negative H. pylori EIA serology, 95.5% were positive in 
immunoblotting[34]. In a study of  10 patients with severe 
atrophic corpus gastritis, all were H. pylori negative in 
histology and in EIA-serology, and only one was positive 
in immunoblotting[24]. However, in this particular study, 
the immunoblotting method used to measure CagA 
antibodies was less sensitive than EIA-serology in 
detecting an ongoing H. pylori infection. In the present 
study, all except three patients had a positive CagA band 
on the immunoblot, including all EIA-serology positive 
patients. We have studied the sensitivity and specificity of  
this particular immunoblotting method previously, with 
good results[23]. However, not even the immunoblotting 
method used in our present study can rule out a previous 
H. pylori infection with 100% certainty, as all H. pylori 
strains are not CagA positive. On the other hand, the 
common occurrence of  H. pylori antibodies in patients 
with autoimmune type of  atrophic gastritis could be a 
random effect, as the H. pylori infection rate has been 
nearly 100% in populations now presenting as the peak 
age group of  autoimmune gastritis. This could also be 
one explanation why H. pylori prevalence studied by 
immunoblotting in patients with serological markers of  
autoimmune type gastritis (PCA and IF antibodies) was 
no different from patients with no such markers in our 
study. 
Thus, it still remains to be shown if  H. pylori infection 
is crucial for the development of  autoimmune type 
atrophic gastritis. However, bacterial infections might be 
important in autoimmune processes, as recently suggested 
by Torchinsky et al[35]. In this in vitro study, phagocytosis 
of  immune cells infected with bacteria and undergoing 
apoptosis promoted Th17 cell differentiation, the cell 
type having a potential role in autoimmunity. Thus, it 
is tempting to speculate that cells in the gastric mucosa 
infected with H. pylori could trigger an autoimmune 
response.
In conclusion, atrophic corpus gastritis, including 
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autoimmune type severe atrophy with vitamin B12 mal-
absorption, is associated with a longstanding H. pylori 
infection in most cases. There is an urgent need for 
population-based studies to assess the effect of  H. pylori 
eradication on the development of  vitamin B12 malab-
sorption.
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